JOHNSON & JOHNSON is 40.1x more valuable than Jazz Pharmaceuticals plc by market capitalization ($579.83 B vs $14.47 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | JAZZ | JNJ |
|---|---|---|
| Market cap | $14.47 B | $579.83 B |
| US-listed rank | #759 | #20 |
| Revenue (latest FY) | $4.27B | $94.19B |
| Net income (latest FY) | -$356.15M | $26.80B |
| Net margin | -8.3% | 28.5% |
| P/E (trailing FY) | - | 21.6 |
| SEC filings | 2,087 | 984 |
JOHNSON & JOHNSON is 40.1x more valuable than Jazz Pharmaceuticals plc by market capitalization ($579.83 B vs $14.47 B).
In their latest fiscal years, Jazz Pharmaceuticals plc reported $4.27B in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Jazz Pharmaceuticals plc and JOHNSON & JOHNSON, or browse the full rankings.